-
Uncategorized2 weeks agoLast chance to register: Understand LC-MS quantification strategies for proteins
A new event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as...
-
Fierce Biotech2 weeks ago
Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream
Shionogi has struck a deal to take full control of its sleep disorder joint venture, agreeing to pay Apnimed $100 million upfront for its partner’s half...
-
STAT News – Biotech2 weeks agoWhat growing up in an end-times church taught a science communicator about dispelling misinformation
Belief systems, turns out, can be like dams. However established, they can’t survive even the smallest crack: slowly, but inexorably, if somehow a small seed of...
-
STAT News – Biotech2 weeks agoSTAT+: The potential loophole in Trump’s plan to get other countries to pay more for drugs
WASHINGTON — Comments from a top Trump administration health official add to signs of a major flaw in the president’s most-favored nation drug pricing plans. The...
-
STAT News – Biotech2 weeks agoOpinion: Covid followed 5 standard stages of pandemic response — until it became unprecedented
Six years after the Covid shutdown of March 2020, the nation is still struggling to recover from a trauma that has become deeply politicized. Despite a...
-
Endpoints News2 weeks ago
Immutrin secures $86M for antibody program
A British biotech based in Cambridge, England, raised $86 million to advance an antibody drug designed to deplete protein deposits in people with amyloidosis. The company,...
-
Fierce Biotech2 weeks ago
Innovent sees path to China approval after eye disease drug matches Eylea in phase 3
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for Chinese approval of a molecule that...
-
Uncategorized2 weeks ago
Biotechs Must Face Reality To Succeed in Today’s Funding Environment
The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people think.
-
Uncategorized2 weeks ago
Japan’s Drug Prices Are Creating Problems for Washington and Tokyo Alike
If the U.S. can help Japan reform its drug pricing controls, both countries stand to benefit.
-
Fierce Biotech2 weeks ago
Gilead’s $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos
Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.
